Executive Director

Mr. Li Gang (李剛先生) , has accumulated many years of working and corporate management experience in the fields of trading and financial technology. He founded Shenzhen Youbo Network Technology Co., Ltd.（深圳優博網路科技有限公司）and served as the general manager. He has also worked as the product director in Shanghai Mingchuang Software Technology Co., Ltd.（上海銘創軟件技術有限公司）, as the trust manager in Chongqing International Trust Co., Ltd.（重慶國際信託有限公司）and the trust manager in Zhongrong International Trust Co., Ltd.（中融信託有限公司）, and as the investment manager in Munsun Asset Management (Asia) Limited（麥盛資產管理（亞洲）有限公司）. From June 2020 to April 2025, Mr. Li served as the chairman and executive director of Enviro Energy International Holdings Limited, the shares of which are listed on the Stock Exchange with stock code 1102. Mr. Li is currently the director of Wonderland International Investment Holdings Limited（華德國際投資控股有限公司）, Longma International Technology Limited（龍馬國際科技有限公司）, respectively. Mr. Li obtained a bachelor’s degree in engineering from the University of Nanking（南京金陵大學）in 1984.

Non-Executive Directors

Ms. Tan Yanzi（談燕子女士）,  has many years of experience in the fields of power informatization, corporate management and investment. She is currently an investment consultant
of Sunking Pacific Limited（賽晶亞太有限公司）since April 2024 and as a senior management of Beijing Huadian Xiangyun Software System Co., Ltd.*（北京華電祥雲軟件系統有限公司）since 2010.

Ms. Chen Yun (陳雲女士) , joint the Company in May 2017 and has been appointed as an Executive Director on 31 March 2023. She holds a bachelor degree in financial management from Yangzhou University （揚州大學）in the PRC. Prior to joining the Company, Ms. Chen has worked as the financial manager in several property development companies in Zhejiang and Jiangsu Provinces respectively. She served as the Company’s financial controller of the Group’s property segments. She has extensive experience in financial management.

Independent Non-executive Directors

Mr. Mok Yi Kwo (莫儀戈先生), is a Certified Public Accountant (Practising) of the Hong Kong Institute of Certified Public Accountants. He is also a fellow member of the Association of Chartered Certified Accountants. Mr. Mok holds a Bachelor Degree in Business Administration in Accounting and Finance from The University of Hong Kong. He is now running a CPA firm which provides a wide range of professional services in Hong Kong. Before running his own firm, he has been taking up various senior position in various international accounting firms in Hong Kong. Mr. Mok has extensive professional experience in the fields of auditing, accounting, taxation, financial advisory and management for over 20 years.

Ms. Shen Shujiang（沈蜀江女士）, has extensive experience in corporate management, investment management, human resources management and securities affairs. Ms. Shen previously served as securities affairs representative, director of the board office, board secretary and deputy general manager of Shenzhen Hongji (Group) Co., Ltd.*（深圳市鴻基（集團）股份有限公司）(currently know as Tunghsu Azure Renewable Energy Co., Ltd.（東旭藍天新能源股份有限公司）, a company used to be listed on the Shenzhen Stock Exchange (stock code: 000040)) from July 1995 to June 2016. She also served as board secretary and deputy general manager of Shenzhen Comix Group Co., Ltd.（深圳齊心集團股份有限公司）, a company listed on the Shenzhen Stock Exchange (stock code: 002301), from June 2016 to July 2019. Ms. Shen served as an independent director of Vinner Health (Shenzhen) Co., Ltd. *（維尼健康（深圳）股份有限公司）, a company used to be listed on the National Equities Exchange and Quotations (the “NEEQ”) (stock code: 835208), from September 2020 to August 2021, and of Guangzhou ChinaGDN Security Technology Co., Ltd.*（廣州競遠安全技術股份有限公司）, a company listed on the NEEQ (stock code: 870971), from January 2021 to January 2025. Since November 2022, Ms. Shen has been serving as an independent director of Shenzhen Minglida Precision Technology Co., Ltd.（深圳市銘利達精密技術股份有限公司）, a company listed on the Shenzhen Stock Exchange (stock code: 301268). Ms. Shen obtained a bachelor’s degree in business management from Jiangsu University of Science and Technology*（江蘇理工大學）in July 1994. She obtained the intermediate qualification in finance（中級金融資格）from the Shenzhen Professional Title Management Office*（深圳市職稱管理辦公室）in October 1998 and holds the Board Secretary Training Certificate issued by the Shenzhen Stock Exchange in September 1999.

Dr. Gao Xiang（高翔博士）, a veteran in China’s biotech industry, with decades of experience bridging the realms of biotech entrepreneurship and corporate governance. Dr. Gao founded GemPharmatech Co., Ltd.（江蘇集萃藥康生物技術股份有限公司）, a company listed on the Shanghai Stock Exchange (stock code: 688046), in December 2017 and has been serving as its chairman since then. Dr. Gao has been serving as an independent non-executive director of Alphamab Oncology, a company listed on the Stock Exchange (stock code: 9966) since June 2025. Dr. Gao’s early career was marked by his dedication to academic and laboratory research. From 1997 to 2000, he served as a research associate at the neuroscience center of University of North Carolina. Dr. Gao has been a professor at Nanjing University（南京大學）since March 2000, and was recognized a Yangtze River Scholar Distinguished Professor（長江學者獎勵計劃特聘教授） at the model animal research center in 2001, where he served as director from 2002 to 2012. Dr. Gao also served as the dean of the Nanjing Biomedical Research Institute of Nanjing University from 2009 to 2018, concurrently holding the position of director of the state key laboratory of pharmaceutical biotechnology. Beyond those roles, Dr. Gao was a director of the key laboratory of Model Animal and Disease Research（模式動物與疾病研究）of the Ministry of Education (MOE) from 2010 to 2015, and has been the director of the National Resource Center for Mutant Mice（國家遺傳工程小鼠資源庫）since 2002. Dr. Gao also holds multiple roles in academic societies, including, among others, member of the National Laboratory Animal Professional Committee（國家實驗動物專家委員會）, and member of the steering committee of the International Mouse Phenotyping Consortium（國際小鼠表型分析聯盟）. Dr. Gao has led numerous national research projects under, among others, the National 973 Program, 863 Program and Science and Technology Support Program. His outstanding contributions to scientific research have been recognized with prestigious awards, such as the National Science Fund for Distinguished Young Scholars（國家傑出青年科學基金）, the Special Prize of the MOE Award for Scientific and
Technological Progress（教育部科技進步特等獎）and the Second Prize of the State Scientific and Technological Progress Award（國家科技進步二等獎）. Dr. Gao obtained a bachelor’s degree in zoology and a master’s degree in biochemistry from Nanjing University in 1985 and 1988, respectively. He further obtained a Ph.D. in developmental biology and anatomy from Thomas Jefferson University in the United States in 1994. From 1994 to 1997, Dr. Gao successively conducted his postdoctoral research in Roche Institute of Molecular Biology and The Jackson Laboratory, both in the United States.